Related Experiment Videos
A hereditary cancer consultation clinic
The Nebraska Medical Journal
|December 1, 1989
Summary
Bridging the gap in hereditary cancer care requires increased awareness, cost-benefit data for management, and improved patient compliance. Future research into biomarkers and genetic therapies aims to prevent cancer expression.
Area of Science:
- Oncology
- Genetics
- Public Health
Background:
- Hereditary cancers represent a significant portion of the overall cancer burden.
- A substantial gap exists between current knowledge of hereditary cancer genetics and its clinical application.
Observation:
- The Hereditary Cancer Clinical Care (HCCC) concept is proposed to bridge the knowledge-to-application gap.
- Key areas for success include public and physician education, cost-benefit analyses for surveillance, and enhanced patient compliance.
Findings:
- Implementing the HCCC model necessitates greater awareness of hereditary cancer's prevalence.
- Generating cost-benefit data is crucial for third-party payer responsiveness to patient needs in hereditary cancer management.
- Improving patient and family adherence to surveillance protocols can lead to earlier cancer detection and better survival rates.
Implications:
- Future research should focus on identifying sensitive and specific biomarkers for cancer-prone genotypes.
- The ultimate goal is to develop biochemical agents to ameliorate the effects of deleterious genes, improve clinical outcomes, or prevent cancer development.
- Translating genetic knowledge into effective clinical strategies is essential for advancing hereditary cancer care.